Leea indica

Leea indica leaf extracts contain phenolic acids (gallic acid, ellagic acid), flavonoids (quercetin-3-O-rhamnoside, myricetin-3-O-rhamnoside), catechins (epigallocatechin-3-O-gallate), and novel dihydrochalcones that collectively act as free radical scavengers, protein-denaturation inhibitors, and membrane-stabilizing agents. In vitro, the ethanol leaf extract demonstrates DPPH radical scavenging up to 70.55 ± 1.16% at 0.02 mg/ml, total phenolic content of 24.00 ± 0.81 g GAE/100 g dry extract, and antimicrobial activity with MIC values as low as 25 µg/ml against Gram-positive bacteria such as Bacillus cereus and Bacillus megaterium.

Origin & History

Leea indica is native to tropical and subtropical Asia, distributed across Southeast Asia including Thailand, Malaysia, Indonesia, the Philippines, and extending into South Asia and parts of Oceania. It grows as a shrub or small tree in disturbed forests, forest margins, and secondary vegetation, thriving in humid, lowland to mid-elevation tropical climates with rich, moist soils. The plant has a long history of semi-wild collection for medicinal use rather than formal cultivation, and it belongs to the family Vitaceae, making it a relative of grapevines.

Historical & Cultural Context

Leea indica is part of a genus in which approximately half of all species carry documented medicinal applications across South and Southeast Asian traditional medicine systems, reflecting centuries of empirical use by indigenous and rural communities. In Thai traditional medicine, the plant is specifically cited for treatment of bone fractures, where leaf preparations are applied topically or administered as decoctions to accelerate healing, a use consistent with the plant's anti-inflammatory and possibly pro-angiogenic phenolic profile. Across broader Southeast Asia, Leea species have been employed for skin disorders, fever, rheumatic complaints, and wound care, with preparations typically involving direct maceration of fresh leaves, bark decoctions, or poultice applications. No major classical pharmacopoeial text (such as Ayurvedic or Chinese pharmacopoeias) formally documents Leea indica as a primary medicinal entry, placing it primarily within the domain of local folk and ethnomedical knowledge systems rather than formally codified herbal traditions.

Health Benefits

- **Antioxidant Protection**: Leaf ethanol extracts deliver DPPH free radical scavenging of up to 70.55 ± 1.16% at 0.02 mg/ml and superoxide dismutase inhibition, with a total antioxidant capacity of 106.61 ± 1.84 g ascorbic acid equivalents per 100 g dry extract, driven primarily by gallic acid, epigallocatechin-3-O-gallate, and quercetin derivatives.
- **Anti-Inflammatory Activity**: Acetone and methanol extracts inhibit bovine serum albumin denaturation and erythrocyte hemolysis with IC50 values of 431.5 µg/ml and 442.1 µg/ml respectively, outperforming aspirin (IC50 1062 µg/ml) in the same assay, suggesting membrane-stabilizing flavonoids and phenolic acids are responsible.
- **Antimicrobial Properties**: Ethyl acetate and methanol fractions exhibit broad-spectrum antimicrobial activity with MIC values of 25–100 µg/ml; Gram-positive pathogens including Bacillus cereus and Bacillus megaterium are particularly susceptible at 25 µg/ml, attributed to gallic acid and catechin disruption of bacterial cell membrane integrity.
- **Cytotoxic and Antiproliferative Potential**: Brine shrimp lethality assays reveal significant cytotoxicity compared to the reference compound vincristine sulfate, with novel dihydrochalcones isolated from the ethyl acetate fraction—including 4′,6′-dihydroxy-4-methoxydihydrochalcone 2′-O-β-D-glucopyranoside—considered candidate structures for further antiproliferative investigation.
- **Analgesic Support**: Preclinical animal models document analgesic effects from Leea indica extracts, consistent with anti-inflammatory phenolic constituents that may modulate pain pathways by reducing prostaglandin-mediated inflammation, though specific molecular targets have not been confirmed in direct mechanistic studies.
- **Antidiabetic Activity**: Preclinical evidence indicates antidiabetic effects, plausibly mediated by polyphenols such as quercetin-3-O-rhamnoside and myricetin-3-O-rhamnoside that are known alpha-glucosidase inhibitors in related species, reducing postprandial glucose absorption, though no direct enzyme inhibition data specific to Leea indica has been published.
- **Traditional Fracture and Wound Healing**: In Thai ethnomedicine, Leea indica is applied for bone fractures and wound management; while no clinical validation exists, gallic acid and ellagic acid possess documented collagen-stabilizing and pro-angiogenic properties in other systems that may underpin this traditional use.

How It Works

The antioxidant mechanism operates through hydrogen atom transfer and single electron transfer by polyhydroxylated flavonoids (quercetin, myricetin, kaempferol derivatives) and gallotannins (gallic acid, methyl gallate, epigallocatechin-3-O-gallate), which donate electrons to DPPH, superoxide, and hydroxyl radicals, simultaneously chelating pro-oxidant transition metals via ortho-dihydroxy catechol moieties. Anti-inflammatory activity involves stabilization of protein tertiary structure against heat-induced denaturation and inhibition of osmotic hemolysis, effects attributed to membrane-intercalating flavonoid glycosides and phenolic acids that reduce phospholipid bilayer permeability and may suppress NF-κB-mediated cytokine transcription by analogy with structurally related compounds. Antimicrobial action is mediated by gallic acid and catechin-class compounds that increase bacterial membrane permeability, inhibit cell wall biosynthesis enzymes, and complex with bacterial surface proteins, producing concentration-dependent bacteriostatic to bactericidal effects at MIC 25–100 µg/ml. The novel dihydrochalcone glycosides unique to this species may interact with topoisomerase or tubulin targets consistent with cytotoxic chalcone pharmacophores, though direct receptor-level confirmation in Leea indica has not been published.

Scientific Research

The current evidence base for Leea indica consists entirely of in vitro phytochemical and bioassay studies and preclinical animal experiments; no peer-reviewed human clinical trials have been published as of the available data. Key in vitro studies have characterized leaf extracts using HPLC-MS, NMR, Folin-Ciocalteu, DPPH, disk diffusion, and brine shrimp lethality assays, reporting reproducible antioxidant, antimicrobial, anti-inflammatory, and cytotoxic endpoints with quantified IC50, MIC, TPC, and TFC values. Preclinical animal studies document analgesic, antidiabetic, anti-inflammatory, antimicrobial, antioxidant, and antiproliferative activities without published sample sizes, effect sizes, or standardized dose-response curves in available literature, limiting extrapolation to human therapeutics. The evidence quality is low overall—consistent with a 4/10 evidence score—reflecting solid phytochemical characterization but a complete absence of pharmacokinetic, bioavailability, or clinical outcome data.

Clinical Summary

No human clinical trials investigating Leea indica for any indication have been identified in the available scientific literature. All efficacy data derive from cell-free radical scavenging assays, bacterial disk diffusion, protein denaturation inhibition models, brine shrimp lethality tests, and unspecified animal models, none of which provide the controlled conditions or human outcome measures required to establish clinical efficacy or safety. Effect sizes from in vitro studies are promising—particularly the DPPH scavenging exceeding 70% at microgram-per-milliliter concentrations and MIC values competitive with standard antimicrobials—but these cannot be translated directly into therapeutic recommendations. Confidence in any clinical claim remains very low, and Leea indica should be regarded as a candidate for phytopharmaceutical development rather than an evidence-based clinical intervention.

Nutritional Profile

Leea indica leaves are not consumed as a dietary staple and no comprehensive macronutrient or micronutrient profile has been published. The dominant nutritionally relevant constituents are phenolic phytochemicals: total phenolic content reaches 24.00 ± 0.81 g gallic acid equivalents per 100 g dry ethanol extract (up to 37.29 mg GAE/g in water fractions), and total flavonoid content is 194.68 ± 2.43 g quercetin equivalents per 100 g dry extract, indicating a highly polyphenol-dense leaf matrix. Identified phytochemicals include gallic acid, methyl gallate, ellagic acid, epigallocatechin-3-O-gallate, gallocatechin, epigallocatechin, quercetin-3-O-rhamnoside, myricetin-3-O-rhamnoside, kaempferol, quercitrin, myricitrin, phloridzin derivatives, dimeric catechins, three novel dihydrochalcone glucosides, alkaloids, and terpenoids. Bioavailability of leaf polyphenols is expected to be subject to the same first-pass metabolism, microbial biotransformation, and matrix-dependent absorption limitations that govern polyphenol bioavailability generally, but no pharmacokinetic studies specific to Leea indica have been conducted.

Preparation & Dosage

- **Crude Leaf Powder (Traditional/Ethnomedicinal)**: No standardized dose established; Thai traditional use for fractures involves topical poultice or decoction preparation from fresh or dried leaves at unspecified quantities.
- **Ethanol Extract (Research Grade)**: In vitro studies use concentrations of 0.002–20 mg/ml; no human-equivalent dose calculated or validated.
- **Aqueous Decoction (Traditional)**: Leaves boiled in water for oral or topical application; water extracts show highest TPC at up to 37.29 mg GAE/g extract but no preparation volume or frequency standardized.
- **Ethyl Acetate Fraction (Phytochemical Isolation)**: Used at research scale to isolate gallic acid, catechins, and dihydrochalcones; not available as a consumer supplement.
- **Acetone/Methanol Extract (Anti-inflammatory Assays)**: IC50 values determined at 431–442 µg/ml in protein denaturation assays; no clinical dosing protocol derived.
- **Standardization**: No commercial supplement is currently standardized for any Leea indica constituent; total phenolic content (as GAE) or total flavonoid content (as quercetin equivalents) would be logical standardization targets for future product development.
- **Timing**: No clinical timing data available; traditional use is context-dependent and empirical.

Synergy & Pairings

Based on the flavonoid and gallotannin composition of Leea indica, co-administration with vitamin C (ascorbic acid) is theoretically synergistic, as ascorbate regenerates oxidized flavonoid radicals back to their active reduced forms, prolonging antioxidant activity—a mechanism well-documented for quercetin-ascorbate combinations in vitro. The catechin fraction (particularly epigallocatechin-3-O-gallate) may exhibit additive antimicrobial synergy with conventional antibiotics against Gram-positive pathogens by disrupting cell membrane integrity and lowering effective antibiotic MIC values, a pattern observed with EGCG-antibiotic combinations in related plant systems. Pairing with piperine (from black pepper) or a lipid-based carrier could theoretically improve the poor oral bioavailability of the polyphenol-rich extract, as piperine inhibits UDP-glucuronosyltransferase and P-glycoprotein efflux, increasing systemic exposure to quercetin and catechin metabolites.

Safety & Interactions

Formal toxicological profiling of Leea indica in humans is absent from the published literature, and no maximum safe dose, NOAEL, or clinical adverse event profile has been established. The brine shrimp lethality assay indicates meaningful cytotoxicity (significant LC50 relative to vincristine sulfate), which—while used as a proxy for antiproliferative potential—also raises a theoretical concern about cellular toxicity at higher concentrations that warrants formal mammalian toxicology studies before human use. No specific drug interactions, contraindications, or guidance for pregnancy and lactation have been reported; however, the high tannin and catechin content suggests a theoretical risk of interference with iron absorption and possibly reduced bioavailability of orally co-administered drugs that bind to polyphenols. Until systematic toxicology, genotoxicity, and pharmacokinetic studies are completed, Leea indica preparations should be used with caution outside traditional ethnomedicinal contexts, and use during pregnancy, lactation, or alongside anticoagulant, antidiabetic, or immunosuppressive medications requires medical supervision.